Objectives This systematic review and meta-analysis of randomized controlled trials (RCTs)
aimed to investigate the clinical efficacy and safety of tocilizumab for treating patients with …

Background Preliminary data from severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) pneumonia patients indicate that a cytokine storm may increase morbidity and …

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …

Patients with coronavirus disease 2019 (COVID‐19) may develop severe respiratory
distress, thought to be mediated by cytokine release. Elevated proinflammatory markers …

Nearly 10 months after the identification of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) as the virus responsible for coronavirus disease 2019 (Covid-19) …

The coronavirus disease 2019 (COVID-19) has caused a global pandemic, resulting in
considerable morbidity and mortality. Tocilizumab, an inhibitor of IL-6, has been widely …

Tocilizumab is an interleukin (IL)‐6 receptor inhibitor that has been proposed as a
therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this …

Objectives Tocilizumab has been proposed as a candidate therapy for patients with severe
coronavirus disease 2019 (COVID-19), especially among those with higher systemic …

Introduction We systematically assessed benefits and harms of tocilizumab (TCZ), which is
an antibody blocking IL-6 receptors, in hospitalized COVID-19 patients. Methods Five …

Background The clinical presentation of SARS-CoV-2 infection ranges from mild symptoms
to severe complications, including acute respiratory distress syndrome. In this syndrome …